Monsanto Roundup Lawsuit


Citizens Commission on Human Rights Award Recipient (Twice)
Humanist, humorist

Thursday, October 07, 2010

GSK - THE PAXIL FILES

SPECIAL THANKS TO DOUG BREMNER, CHRISTOPHER LANE AND HEALTHY SKEPTICISM FOR MAKING SOME OF THESE DOCUMENTS AVAILABLE






PAXIL/SEROXAT - GREATEST NUMBER OF SUICIDE ATTEMPTS


----


GSK PAXIL CASPPER DOCUMENT


----


GLAXOSMITHKLINE PROGRAM CALLED “PSYCHNET”


----


FOREWORD BY PAUL N. JENNER, DIRECTOR AND VICE PRESIDENT OF NEUROSCIENCE AND STRATEGIC PRODUCT DEVELOPMENT


----


SECTION 1: TOWARDS THE SECTION BILLION -- ALL SSRI'S ARE NOT THE SAME


----


SECTION 2: NEW INDICATIONS: SOCIAL ANXIETY DISORDER / SOCIAL PHOBIA


----


SECTION 3: ISSUES MANAGEMENT: MANAGING THE DISCONTINUATION ISSUE

----

"DURATION OF TREATMENT AND DEPRESSION: RELAPSE AND RECURRENCE RATES"

----

"PAXIL CR" PRODUCT MONOGRAPH


----


PAXIL LITIGATION DOCUMENTS


----


GSK's PAXIL.COM...STILL A WEALTH OF [DIS] INFORMATION


----


DOCUMENT RETENTION, LETTERS TO MINISTERS, LETTERS AND EMAILS ABOUT SEROXAT AND LIST OF FOI REQUESTS


----


MINUTES OF MEETING BETWEEN MHRA AND BOB FIDDAMAN


----


PRESS RELEASE: GSK INVESTIGATION CONCLUDES


----


MHRA INVESTIGATION INTO GLAXOSMITHKLINE/SEROXAT


----


GSK SEROXAT - LETTER TO GSK FROM MHRA


----


GSK SEROXAT - LETTER TO TRADE ASSOCIATIONS


----


SUMMARY OF REGULATORY ACTION


----


LETTER FROM GSK CHIEF MEDICAL OFFICER TO MHRA


----


MHRA RESPONSE TO LETTER FROM GSK CHIEF MEDICAL OFFICER


----


PAXIL STUDY 329 ALL OVER AGAIN?
Article By Bob Fiddaman



----


MARKET SENTINEL'S STAKEHOLDER ANALYSIS COMMISSIONED BY THE UK MHRA TO ASSESS PUBLIC DISCUSSION OF THE SEROXAT CONTROVERSY


----


KILKER V GLAXOSMITHKLINE COURT TRANSCRIPTS

----


PAXIL STUDY 329: PAROXETINE vs IMIPRAMINE vs PLACEBO IN ADOLESCENTS


Fid

ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING

Please contact me if you would like a guest post considered for publication on my blog.